Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Biotechnology

Healthcare
$4.26 +2.67%

+$0.19 today

Market cap
$71.70M
Beta
1.52
P/E (TTM)
0.0
EPS (TTM)
$407.81
52W Low $6.42High $31.50

Volume 0.06M

Average 0.44M

ENLV Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Enlivex Therapeutics Ltd.NASDAQ: ENLV

Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Financing cash flow growth accelerates

Q4 FY2025 financing cash flow of $10.44M rose 727.6% year over year, ahead of the +70.2% change in trailing-twelve-month financing cash flow. Sequentially, it rose 2864.8% from the prior quarter. Over 3 fiscal years it compounded at +310.6% a year.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +727.6% holds above the trailing-twelve-month pace of +70.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$10.44M+2864.8% QoQ
Last fiscal yearDec 2025
$10.38M+60.8% YoY
LTMDec 2025
$10.99M+70.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+727.6%——
1 year+60.8%——
3-year CAGR+310.6%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
10.38M USD
Year-over-year change
+60.8%
4-year CAGR
-35.8%

Financing Cash Flow vs competitors

How ENLV compares with its peers on the latest reported figures

  • ENLV's LTM Dec 2025 financing cash flow of $10.99M is the smallest of the 2 companies compared; the peer median is $11.25M.
  • Its year-over-year change of +70.2% is the highest of 2, against a peer median of +35.1%.
  • Over three fiscal years its annual growth of +310.6% compares with a peer median of +50.6%.
ENLV Competitors Peer median
Financing Cash Flow for ENLV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRXSNeurAxis, Inc.LTM Mar 2026$11.25M +35.1%+50.6%262.6%
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$10.99M +70.2%+310.6%—
Peer median (excluding ENLV) $11.25M+35.1%+50.6%262.6%

Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.47M)(31.06M)(29.07M)(15.01M)1.24B
Depreciation & Amortization546K777K835K545K332K
Deferred Income Tax(5.59M)000382.65M
Stock-Based Compensation2.91M2.71M1.95M2.07M1.78M
Change in Working Capital(1.36M)804K(1.82M)(1.22M)815K
Accounts Receivables(1.25M)278K608K433K(3.05M)
Inventory1.25M(278K)000
Accounts Payables442K1.17M(1.12M)(16K)3M
Other Working Capital(1.8M)(364K)(1.31M)(1.64M)869K
Other Non-Cash Items413K2.81M4.58M614K(1.63B)
Operating Cash Flow(17.54M)(23.95M)(23.52M)(13.01M)(10.42M)
Capital Expenditures(1.63M)(8.12M)(236K)(103K)(68K)
Acquisitions (Net)(20.03M)(9.71M)001.38M
Purchases of Investments(104.42M)(1.61M)(26.17M)(32.37M)(24.5M)
Sales of Investments67.63M72.25M301K39.24M41.37M
Other Investing Activities20.03M9.71M133K2.29M0
Investing Cash Flow(38.41M)62.52M(25.97M)9.06M(1.32M)
Debt Repayment00000
Common Stock Issued53.17M150K360K6.45M10.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.81M002K0
Financing Cash Flow60.98M150K360K6.45M10.38M
Effect of Forex Changes(408K)(91K)00(49K)
Net Change in Cash4.62M38.72M(49.13M)2.51M(1.41M)
Free Cash Flow(19.17M)(32.08M)(23.76M)(13.11M)(10.48M)

Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Intrinsic Alpha fair value

Locked

Current Price

$4.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.